Drugs / MTM-H-001
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT07593911 | Jun 2026 → Nov 2030 expected | immunoglobulin G4-related sclerosing disease, lupus nephritis, multiple sclerosis, myasthenia gravis +2 | Beijing GoBroad Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07476378 | Mar 2026 → Jan 2028 expected | chronic lymphocytic leukemia/small lymphocytic lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma +1 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Not yet recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MTM-H-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07476378 ↗ |